(Avibactam + aztreonam) is under clinical development by Pfizer and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect (Avibactam + aztreonam)’s likelihood of approval (LoA) and phase transition for Bacterial Pneumonia took place on 20 Dec 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 20 Dec 2021 increased (Avibactam + aztreonam)’s LoA and PTSR for Complicated Intra-Abdominal Infections, increased LoA and PTSR for Gram-Negative Bacterial Infections, increased LoA and PTSR for Hospital Acquired Pneumonia (HAP), increased LoA and PTSR for Peritonitis, and increased LoA and PTSR for Ventilator Associated Pneumonia (VAP).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Avibactam + aztreonam) Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

(Avibactam + aztreonam) overview

PF-06947387 (aztreonam in combination with avibactam) is under development for the treatment of serious gram-negative bacterial infections caused by multiple-drug resistant pathogens producing metallo-beta-lactamases such as hospital-acquired pneumonia, ventilator-acquired pneumonia, complicated intra-abdominal infections, complicated urinary tract infections, peritonitis and bacterial pneumonia. The combination therapy is administered intravenously as a solution. It is a new molecular entity.

Pfizer overview

Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.

Quick View (Avibactam + aztreonam) LOA Data

Report Segments
  • Innovator
Drug Name
  • (Avibactam + aztreonam)
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.